Image source: The Motley Fool.
Amneal Pharmaceuticals, Inc. (AMRX -0.25%)
Q4Â 2019 Earnings Call
Feb 26, 2020, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and welcome to the Amneal Pharmaceuticals' Fourth Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
I would now like to turn the conference over to Todd Branning, CFO. Please go ahead.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Thank you, and good morning, everyone. Welcome to Amneal's fourth quarter 2019 earnings call. Earlier this morning, we issued a press release reporting our quarterly results. The press releases as well as the slides that will be presented on this call are available on our website at www.amneal.com. We are conducting a live webcast of this call, a replay of which will also be available on our website after its conclusion.
Please note that today's call is copyrighted material of Amneal and cannot be rebroadcast without the Company's expressed written consent. I would also like to remind you that during the course of this call, management will make projections or other forward-looking remarks regarding future events or the future financial performance of the Company.
It's important to note that such statements about estimated or anticipated Amneal results, prospects or other non-historical facts are forward-looking statements and reflect our current perspective of existing trends and information as of today's date. Amneal disclaims any intent or obligation to update these forward-looking statements except as expressly required by the law. Actual results may differ materially from current expectations and projections depending on a number of factors affecting the Amneal business. These factors are detailed in our periodic public filings with the Securities and Exchange Commission, including, but not limited to, the Amneal Pharmaceuticals, Inc. Form 10-K.
Our discussion today also includes certain non-GAAP measures as defined by the SEC. Management uses both GAAP financial measures and the disclosed non-GAAP financial measures internally to evaluate and manage the Company's operations and to better understand the business. Further, management believes the inclusion of non-GAAP financial measures provides meaningful supplementary information to and facilitates analysis by investors in evaluating the Company's financial performance, results of operations and trends. A reconciliation of GAAP to non-GAAP measures is available in this morning's press release and in the appendix of today's presentation.
Joining me on the call this morning are Chirag Patel and Chintu Patel, our Co-CEOs. Following the prepared remarks, we will hold a Q&A session. Also on the call and available for Q&A are Andy Boyer, our Executive Vice President of Commercial Operations; Joe Todisco, Senior Vice President of Specialty Commercial; and Steve Manzano, our General Counsel and Corporate Secretary.
For our agenda today, Chirag and Chintu will begin with a discussion on our strategic direction. I will then review detailed financial results. Finally, we will have a question-and-answer session following the prepared remarks. And with that, I would like to turn the call over to Chirag.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Todd. Good morning, everyone, and thank you for joining us today to review Amneal's fourth quarter and full year results. When Chintu and I rejoined Amneal as Co-CEOs in August, we laid out our plan to put the Company back on track and lead it in its next phase of growth. We told you that we would revitalize our generics business, continue to grow the specialty franchise and improve our margins and cash flow; expand into international markets and evaluate strategic M&A. And in the last seven months, we have taken steps to do just that.
We have launched 15 new generic products, including high-value first-to-market ones like NuvaRing and Carafate, have one new award for our base business, we have seen continued script growth for key specialty products Rytary and Unithroid, we have already increased our generics gross margin by 350 basis points from Q3 to Q4 2019 and continue to make progress. We have entered into a collaboration with Fosun Pharma to enter the Chinese market with certain products from our product portfolio. And we have executed on the acquisition of a majority stake in AvKARE, which diversifies our channel mix and provides an attractive durable revenue stream. As you can see our efforts are already bearing fruit. Our fourth quarter results build on the momentum from the third quarter and demonstrate that our strategies are working and these result sets up nicely to enter 2020 with strong momentum.
Now, let me turn to the specifics. When we founded Amneal, our goal was to provide access and affordability for prescription drugs. For nearly two decades, we have done just that and today is no different. The industry is changing quickly and significantly. To continue to differentiate Amneal, we recognize that our playbook and strategy need to evolve as well. As a result, we have made a number of critical operational and strategic decisions that we are confident will keep us at the forefront of our industry. Amneal is well capitalized and this has enabled us to move swiftly and strategically as we build Amneal 2.0, which will position us for long-term growth regardless of the competitive landscape.
The path to reinvigorating the big business began last summer. Let's explore our progress on the core tenets of our program that I summarized earlier. First and foremost, we are revitalizing our generics business. We are committed to supporting both our retail and institutional customers and we have been working closely with them to ensure we deliver the high quality, affordable and complex products they need. On this note, I would like to thank all our customers for their collaboration and support. Chintu will cover more of these in detail, but at a high level we have already begun to better leverage our strong existing assets and ensuring new product launch preparedness and execution.
In the second half of 2019 alone, we won new awards of 30 base business products and have 30 additional product opportunities in works. We have launched 15 new products since returning as CEOs, including two first to market launches that I believe highlight Amneal's differentiated capabilities and underscore our ability to continue winning in the market. Beyond the strength of our generics business, we have a growing specialty franchise that we believe will drive meaningful results in 2020 and beyond. We have a lot of exciting opportunities, including continuing to meaningfully grow Rytary where 2019 year-over-year script growth was over 8%; Unithroid where scripts grew by almost 20% in 2019; our IPX203 development program; our licensing agreement with Kashiv BioSciences for exclusive viewers' rights for development and commercialization of K-127; our focus on adding assets to our existing neurology and endocrinology franchise through both M&A and in licensing opportunities; and opportunistic expansion into other therapeutic areas, including additional biosimilars.
Importantly, we are also focused on diversifying the business intelligently. When I talk about diversification, we are focused in two main areas, channels and geographies. Let's talk about the channels first. Through our acquisition of a majority stake in AvKARE, which closed on January 31st and operates as an independent subsidiary, we gained a differentiated platform that provides Amneal and other manufacturers a unique opportunity to diversify our business and open growth opportunities in the large, complex and growing federal healthcare market.
This transaction makes particular sense given our large US manufacturing footprint and recent court ruling regarding TAA compliance. AvKARE has already won 34 national contracts and we expect that number to grow. The AvKARE platform also provides us an opportunity to sell more unit dose products, which is niche and a highly profitable business.
Next is our focus on geographic diversification. At the JPMorgan Healthcare Conference in January 2020, I mentioned that we were looking at international expansion opportunities. In the late 2019, we entered into a licence and supply agreement with Fosun Pharma, who is the leading player in pharmaceutical manufacturing and distribution in China. Our partnership with Fosun Pharma represents a significant opportunity for Amneal to leverage certain products from our US portfolio and efficient manufacturing network. We are gaining access to a rapidly growing generics market as China transitions to competitive bidding for branded and generic pharmaceutical products.
Finally, we remain committed to best-in-class governance. We recently strengthened our Board of Directors with the additions of three new Independent Directors, Jeff George, who served as the CEO of Sandoz and Alcon; Shlomo Yanai, former CEO of Teva; John Keely, a former Senior and Assurance partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, chemical and medical device sector. Our ability to attract leaders of this caliber to our Board is a terrific reflection of Amneal and our future prospects.
We have been relentless in our execution over the last several months. We are pleased that we begin to see results in the fourth quarter and looking forward to building on our momentum in 2020 and beyond. Let me now turn it over to Chintu.
Chintu Patel -- Co-Chief Executive Officer
Thank you, Chirag. I would like to start by reiterating my brother's enthusiasm about the direction of our business. We started to see improvements at the end of the year and we are excited about the opportunities to grow and build on Amneal's strong foundation.
I will start by repeating the point we have made. Since August, our generic business is fundamentally strong. We have over 225 marketed products and a deep pipeline of file [Phonetic] products and ones we are still developing. We have worked hard to earn our reputation of producing high quality products across a variety of complex dosage forms, including injectables, transdermals, topicals and liquids. And we are extremely proud of our impeccable track record in quality and customer service, which has always been a priority for us.
While the industrywide headwinds of increased competition and concentration in buying power contributed to major gross margin declines across the industry over the last few years, the level of compression we saw at Amneal when we took over as Co-CEOs was unacceptable. We have been laser focused in our efforts to improve our margin structure and ultimately reach our target of 40 plus percent gross margin in the generic segment as soon as possible. We have already begun executing on these initiatives.
First, we have improved plant utilization across our manufacturing infrastructure. We oversaw the transfer of many lower value oral solid products to our sites in India, which have more competitive cost structures. We have already increased volume for our complex products, including transdermals, liquids, rings and injectables, which has improved absorption at the plant level. And as Chirag mentioned, we have proactively won additional incremental awards for base business products, 30 in the second half of last year alone, which will have a material impact on our utilization this year.
Second, we have taken steps to strengthen our supply chain and manage cost across the organization. We have addressed operational inefficiencies and are working diligently with our customers to ensure we are delivering the right mix of products to meet their needs, which we expect to lower our rates of inventory obsolescence, and we are already seeing results. Our failures to supply penalties in quarter four were significantly lower than quarter three. These efforts affect the entire supply chain and will help ensure our competitive position going forward.
Third, we continue to successfully get high value, high margin products approved and launched. We previously told you we would launch at least 15 high value products over the next 18 to 24 months. Since rejoining in August, we have already launched four, including generic version of NuvaRing and Carafate, which are first to market opportunities. As we launch more products with limited competition, our margins will naturally increase as well.
Finally, we have a renewed focus on operational excellence. When we previously ran Amneal, we had some of the highest gross margins in the industry. We accomplished this through a relentless pursuit of cost reduction in all areas of our business, including bringing manufacturing in-house and reducing reliance on CMOs. So far, we are pleased with the results, which include strengthening our forecasting, improving coordination and cross finance, operations, supply chain and our customers. And also leveraging our scalability and network of reliable suppliers. And this is -- this isn't an initiative with end date, it is a constant process and one we look forward to building upon. Since we took over in August and a direct result of the four buckets I just outlined, we are pleased to have achieved generic gross margin expansion of 350 basis points from quarter three to quarter four, 2019. And we believe this is just the beginning.
Now turning to R&D. As with any pharmaceutical company, this is the engine for our growth. And given the ever-changing landscape of the industry, we have to be especially thoughtful with our R&D spend. We acknowledge that the ROI for small molecule generic is not what it used to be. The focus needs to be on quality of pipeline, not quantity of products within it, as well as the product selection and the ability to execute and successfully launch high-value generics.
We expect to file 20 to 25 products in 2020 and many of these are potential first to market opportunities as well. We have 97 products in the pipeline waiting for FDA approval and 80 products in the development pipeline. And unlike many of our competitors, we have expertise in both complex product development and manufacturing which reduces our reliance on third parties and gives us better economics on high-value products. And we have just begun to utilize excellent R&D and regulatory infrastructure to pursue ex-US opportunities. As you can imagine, a large hurdle of launching drugs internationally is getting the regulatory process right.
We recognize that many of our products have global opportunity and the process of expanding geographically starts with R&D. We have already begun augmenting our existing team as we move forward with our collaboration with Fosun Pharma and we will make sure we have the right people and resources to execute on this significant opportunity. Generic drug development may have changed, but we continue to see opportunity in high ROI projects.
Turning now to our specialty franchise. We have a solid, scalable foundation and infrastructure in specialty and see significant opportunities for value creation and gross margin across the segment. It is a meaningful part of our business and going forward, we expect to allocate a significant amount of our R&D budget to specialty. As we grow this business, we will continue to be very thoughtful about product selection and leveraging our existing infrastructure. We continue to invest selectively in several key pipeline assets. Our IPX203 development program continues to move forward and we expect top line data from over pivotal Phase 3 study in the first half of 2021. We recently presented data from our previous Phase 2a and 2b studies, which showed statistically significant improvement versus immediate release carbidopa-levodopa combination for key endpoints.
We are excited about the potential for this product and what it could do to improve the lives of Parkinson's disease patients beyond what we have done with Rytary. Our current expectation is to begin commercialization no later than 2023. As Chirag alluded earlier, we also entered into a licensing agreement with Kashiv BioSciences in November, which expands our CNS pipeline into neuromuscular disorder. As part of this agreement, Amneal now has exclusive rights within the US to the new drug application and commercialization of K-127 for the treatment of Myasthenia Gravis. We expect to file this by end of 2021.
For biosimilars, we have three candidates currently in the pipeline, biosimilar version of Neupogen, Neulasta and Avastin, and are actively working to add additional products. Our current focus is oncology and at the time of commercialization, we plan to supplement our existing managed care and commercial operations with new oncology-focused resources in sales and marketing. While it's early days, we fully expect to become one of the key biosimilar players in the US market.
In summary, we look forward to adding more specialty assets where we can leverage our existing development and commercialization capabilities. Before I turn the call over to Todd, I want to thank all employees, customers and suppliers for their continued support. Todd?
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Thanks, Chintu. Good morning, everyone. Before I dive into our results from the fourth quarter, I would like to express my enthusiasm at the positive trends we are seeing as we move into 2020. We continue to face a challenging generics marketplace, but the work we have done to address internal inefficiencies and better position Amneal to capitalize on growth opportunities has already had a positive impact on our financial results. We believe we are well-positioned to build on this momentum through 2020 and beyond.
Now turning to the results. Total net revenue in the fourth quarter was $397 million compared to $378 million in this year's third quarter, a 5% sequential increase, driven by sales from new products launched in the fourth quarter including in December, the first generic versions of NuvaRing and Carafate. Gross margin in the fourth quarter improved to 43%, an increase of 350 basis points from the third quarter 2019 due to favorable volume and mix, new product launches and lower inventory obsolescence charges which more than offset price erosion.
We are continuing to actively manage operating expenses across the organization. In the fourth quarter 2019, adjusted R&D and SG&A expenses were $43 million and $64 million respectively, probably in line with our current run rate levels for these expenditures. Adjusted EBITDA and adjusted diluted earnings per share for the fourth quarter 2019 were $81 million and $0.08 respectively, both sequential improvements as a result of higher revenues and better gross margins compared to the third quarter of 2019.
Moving to a review of our generic segment results compared to the third quarter of 2019. Net revenues grew 3%, driven primarily by the launches of generic NuvaRing and generic Carafate. We were pleased to see the expansion of our generics gross margin from the 30% we delivered in the third quarter of 2019 to 33% in the fourth quarter. The fourth quarter gross margin was driven by favorable volume and mix, new product launches and lower inventory obsolescence charges as compared to the third quarter. Our work is not done, however, and we will continue to move aggressively to drive our generics gross margins to our long-term goal of 40% plus, but we believe are trending in the right direction.
Adjusted operating income in the fourth quarter was $49 million, a sequential increase of $9 million compared to the third quarter of 2019. Higher revenue and gross margin expansion drove the sequential increase in adjusted operating income.
Turning now to our specialty segment results. On a year-over-year basis, net revenue increased 11% to $97 million, driven by higher sales of Unithroid and the reclassification of oxymorphone HCI from the generic segment. On a sequential basis, net revenue in the fourth quarter also increased 11% due to higher sales of Rytary, Unithroid and Zomig nasal spray compared to this year's third quarter. Adjusted gross margin for the fourth quarter was 75%, probably in line with our third quarter adjusted gross margin.
On a year-over-year basis, fourth quarter 2019 adjusted operating income declined by $5 million, primarily due to higher managed care rebates and Medicare coverage gap ability. On a sequential basis, adjusted operating income for the fourth quarter increased $5 million to $46 million. This increase was primarily due to product mix, partially offset by higher rebates and coverage gap liability for timing of claims.
Now, for a review of our cash flow and balance sheet information. We ended the fourth quarter with $153 million in cash, down $64 million compared to the third quarter of 2019. Our cash flow from operations in the fourth quarter 2019 was negative $51 million. As I mentioned during our last earnings call, we expected a step down in cash in the fourth quarter due to factors that resulted in a higher cash balance at the end of the third quarter. These included the timing of customer chargeback deductions and expenditure disbursements, both of which came in at the beginning of the fourth quarter rather than at the end of the third quarter as we had expected.
In the fourth quarter 2019, we had shelf stock adjustments and an acceleration of customer credits. These contributed to lower cash collections in the quarter, but we believe these will normalize in 2020. We also believe the pricing actions we took will benefit our gross to net conversion ratio in future periods.
As we look ahead to our full year 2020 financial outlook, we previously expressed our expectation that 2020 would be a growth year for Amneal. That is still our expectation. We also closed the AvKARE transaction at the end of January and the expected contribution from that business for the balance of the year is reflected in our outlook.
In terms of the numbers, we expect annual revenues of between $1.88 billion and $1.98 billion, driven primarily by growth in our generic segment and the additional revenues from AvKARE. We expect adjusted gross margin between 44% and 46%, EBITDA in the range of $400 million to $450 million and adjusted diluted earnings per share of $0.45 per share to $0.60 per share based on weighted average diluted shares outstanding of approximately 300 million shares.
I would note that we will include 100% of the AvKARE EBITDA in our reported adjusted EBITDA figures since non-controlling interest is calculated based on net income not EBITDA. Our adjusted diluted earnings per share calculations will of course account for the 35% non-controlling interest ownership in AvKARE.
Finally, we anticipate 2020 operating cash flow of between $150 million and $200 million and capital expenditures in the range of $60 million to $70 million.
With that, I'll now turn call back over to Chirag.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Todd. While we are proud to be having seen improvement this quarter, we are aware that we still have a long way to go reach our goals. We expect the trends we are seeing to continue as we work aggressively to improve operations and gain greater efficiencies, drive gross margin expansion and generate growth in 2020 and beyond. As we look through challenging market conditions and internal changes, we continue to operate in a solid financial position with no near-term debt maturities or covenant compliance concerns. We are excited to reinvest in the business in the coming quarters years and rebuild Amneal into the leader we know it can be.
Thank you. With that, I'll turn the call back to Todd.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Thank you, Chirag. Before we open up the line for questions, I'd ask that you please limit yourself to one question and one follow-up. So we can get through a number of callers in the queue. So with that, I'll turn the call back to the operator to open it up for questions, please.
Questions and Answers:
Operator
[Operator Instructions] The first question today comes from Elliot Wilbur of Raymond James. Please go ahead.
Elliot Wilbur -- Raymond James -- Analyst
Thanks, good morning. Just a quick couple of questions around the AvKARE business. At the time of acquisition I think you reported that EBITDA was right over -- just over $60 million, just wanted to get a sense of if that's reasonable run rate to expect for full year 2020? And then I also wondered if you give may be top line contribution, just really trying to understand sort of how that business impacts overall margins I assume that that is going to be or actually I don't know the answer. Is that going to be reported as a separate segment or is that going to be consolidated into generic results? But just try to get a sense of how that business impacts the overall margin profile.
And then just as a follow-up, just a macro question hearing a lot of noise out of China with respect to the impact of coronavirus and how that could impact the generic supply chain, seems like companies that are closest to the API world are suggesting there could be issues relatively near-term, others are indicating they've got plenty of safety stock on hand and there shouldn't be issues for a couple of quarters. Just wondering what your perspective is on the issue? Whether there's any Amneal specific risks and what you may be hearing from the overall competitive environment in terms of whether or not there will be a potential negative impact or shortages? Thanks.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Okay. So this is Todd. Thank you for your questions. I'll take the first couple you asked in respect to AvKARE and then ask Chirag and Chintu to answer the last question as it relates to supply chain. So, the adjusted EBITDA amount that we disclosed when we announced AvKARE transaction a little over $60 million is a reasonable run rate for a full year. Of course, that'll be a little less contribution to us in 2020 simply because we closed the transaction at the end of January. And so we'll only get 11 months contribution this year, but you can work still with that figure as an approximate run rate of EBITDA for the business for this year.
In terms of the top line contribution, we're not going to disclose that the revenue estimate for AvKARE today. It will be reported as a separate segment in our results apart from the generic segment and the specialty segment. So, when we report the first quarter, it will be included for a couple months and will be some additional visibility into the financial profile of that business at that time.
Chirag Patel -- Co-Chief Executive Officer and President
Elliot, good morning. So far our exposure due to coronavirus is limited. We expect one product to be impacted over next three months and other products could be in a single-digit at a rate six months plus since we have this -- we have stock and proactively we're working with our API suppliers in India and other parts of the world, Europe, to have alternate key starting materials. So we don't, at this point, see any impact at all.
Chintu Patel -- Co-Chief Executive Officer
And just to add one point, most of our APIs are coming out of India, Europe and US. We only have a single digit API coming from China and as Chirag said, we have taken proactive measures to protect our supply chain and we don't, at this point, anticipate issues over the near term.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Thank you. Operator, we can move to the next question.
Operator
The next question today comes from David Amsellem of Piper Sandler. Please go ahead.
David Amsellem -- Piper Sandler -- Analyst
Thanks. So wanted to focus on your two newest generics, NuvaRing and Carafate. So, on NuvaRing, can you just talk about how much of the market you can supply? And I believe that you have or will file a CV-30 for a more automated manufacturing process. Can you talk about what that means in terms of your ability to supply more of the market? And then in terms of competition on NuvaRing, what are your expectations regarding competitors specifically Teva and Reddy's or even anyone else down the road? And then I guess the same question for Carafate, how should we think about competitive expectations for that product? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, David. Good morning. NuvaRing, we have approximately 16% market share, our CE-30 for the automated machine, fully automated machine has been approved and we are ramping up our production. As we stated earlier, our goal is to get 25% to 30% market share. Competition, we expect in the first half mainly from Teva and even with the competition and authorized generics, we should be able to keep our market share of 25%, 30%. We do not expect other competitors maybe in the late in the year but not through our early part of the year. Moving to Carafate, we have almost 60% market share as AG has launched in January. And we do not expect any competition this year.
David Amsellem -- Piper Sandler -- Analyst
Okay. Thank you.
Chirag Patel -- Co-Chief Executive Officer and President
Thanks. Our next question comes from Gregg Gilbert of SunTrust. Please go ahead.
Gregg Gilbert -- SunTrust -- Analyst
Thank you. Just to follow up first on AvKARE. I was curious if you're seeing any customer concerns or questions for AvKARE now that Amneal is the majority owner, it sounds like you're not expecting any financial disruption but just wanted to see if you have any qualitative comments on how that hand off and the ownership stake has changed anything, if at all? And then my follow-up is for, Chirag and Chintu, curious what your appetite is as well as your flexibility to pursue additional transactions in the relative near-term that can materially diversify the business such as AvKARE, something of that size or larger? Thank you.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Gregg. Good morning. AvKARE actually -- it runs as an independent company and we have a tremendous support as you know the founders have 35% stake, they run the company and they treat every manufacturing partners equally. We have 100 manufacturing partners, tremendous support from the big manufacturers as this is a highly profitable channel for them to sell their products. And AvKARE does a great job of customer service, relationship with manufacturers, so we're actually very excited to grow that business.
On the appetite and flexibility on the new transaction, as we have stated, we are in the game to hit singles and doubles and now we have turned our focus onto specialty. And we're looking at number of potential transaction that can fit real nicely with our neurology basically in CNS field or endocrinology. So, we're very excited to work on those and we could hit singles and doubles. We do have a flexibility to do so.
Gregg Gilbert -- SunTrust -- Analyst
If I could interject just a single or double as AvKARE in that realm or is AvKARE triple or...
Chirag Patel -- Co-Chief Executive Officer and President
Yes. No, that's single and double, yes.
Gregg Gilbert -- SunTrust -- Analyst
Thank you.
Operator
The next question comes from Chris Schott of JPMorgan. Please go ahead.
Chris Schott -- JPMorgan -- Analyst
Great. Thanks very much for the questions. Just the first one here was on the biosimilars. Can you just elaborate a little bit more about the oncology infrastructure you expect you'll need to build out to compete in these markets? And maybe more just strategically, it seems like at least on some of these initial products you're going to be entering the market after a number of competitors have already launched, how does the company differentiate itself given that dynamic?
And it's a very quick one just coming back to the guidance a bit more in gross margins, that's 44% to 46%, can you give us a little more color how that breaks down by division just given the AvKARE inclusion to the P&L. I am just trying to get sense of how we think about kind of generics versus specialty versus AvKARE as we construct to get that 44% to 46%? Thanks very much.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Chris. Good morning. Biosimilar, as you are well aware how it's shaping up, it's more of a -- I call it a quasi-branded business. So we have put that business in our specialty division under the leadership of Joe Todisco who has done a marvelous job leading our oncology and neurology franchise. We are already using our market access team, marketing team, customer support team to get ready for our oncology launches. The force would be added as we get closer to the launches and we plan to add more oncology assets as well.
Your question on a late entry is absolutely valid one as we had a late start on the biosimilars, we don't expect to jump right into a big market share. So if we are fourth or fifth we expect 8%, 10% market share unlike the generics business, but the next version of biosimilars, we intend to be first or second or third to move up the value chain that as we see this business as over 10 years or 15 years, and we are always here to stay as I said earlier, we build the business over time so we patiently will come from behind just like generics. And we'll be one of the key players in biosimilar business.
On a question of a gross margin, I will turn it over to Todd, the 44% to 46% includes all three segments: specialty, generics and AvKARE distribution business. Please, Todd.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Hi, Chris. This is Todd. Thanks for the question. So as we look at 2020 for each of the segments starting with generics, we ended the year roughly mid-30s gross margin, adjusted gross margin that's how well we are starting out in 20202. We think that will improve to probably the upper 30s over the course of 2020 for reasons we talked about on the call, reduction of manufacturing inefficiencies, launch of new products, and improvement in product mix. So, that's where we see that segments coming in our guidance range of 44% to 46%.
Specialty is right around 75% right now that's stable and we expect that stability will continue in 2020. AvKARE, I'm not going to mention that the gross margin we have built into our numbers this morning. It's obviously a bit lower than the generics business given its predominance and distribution but the blended average of everything I just outlined is what puts us in the range of 44% to 46% for the guidance.
Chris Schott -- JPMorgan -- Analyst
Thank you.
Operator
Our next question comes from Balaji Prasad of Barclays. Please go ahead.
Balaji Prasad -- Barclays -- Analyst
Hi, good morning. And congratulations on the results. So, I wanted to explore a bit more -- a bit further on your comments on biosimilars, Chirag. So, is it fair to assume that your next couple of years, next two to three years will be focused on the three products that you've disclosed. And what would you -- how can I anticipate the evolution of your biosimilar strategy pipeline in the timeline and what kind of capital would you deploy behind this? And do you have any partners on any of these products? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Rajiv [Phonetic]. And good morning to you as well. So biosimilars is one of our specialty segment piece of business along with generics and injectable. The evolution, we'll have is obviously the first three products we expect to get approval and launch in the next one, two, three years. We will add on to our biosimilar pipeline by key partnership. Today, we have partnership with Kashiv BioSciences and mAbxience from Spain. We will add more partnership as we go along.
Our focus as I mentioned last time is been on a regulatory and commercial. There's plenty of manufacturing capacity people have built and R&D capacity which we'll utilize with partners and continue on to evolve our -- biosimilars which would be -- we'll build up the pipeline and as you know, oncology could have 10 products, 15 products. And that's only when we are focusing today.
The capital deployment, we believe the way FDA is moving now and this is what is going to make biosimilars more affordable, more accessible and more of a game for players like us and Teva and Mylan and not a game for Pfizer and other Merck and big pharma because the approval requirements where it used to require lengthy trials, we believe would go away. And FDA would work with us on a more on analytical methods, more on PK studies and we may not have to repeat unnecessary big trials of already proven effective products. So that will bring the capital deployment to a more manageable numbers, we don't have exact number but let's say I could -- our appetite is between $25 million to $50 million per biosimilar to spend. And we see this deployment over next five years to build our pipeline.
Balaji Prasad -- Barclays -- Analyst
That's very helpful, Chirag. I have follow-up on the injectables. Firstly, so you had 15 new launches since August, was this just a question of timing of approvals or did the revamp management do anything differently? And on the injectables pipeline, what kind of a timeline would most of this materialize? How should I factor growth around this part of your pipeline? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
So we already market almost 20 injectables products. We have started, but we do have two manufacturing plants of our own. We have a very strong pipeline to add on injectables and become a key player in coming years. Today, we are approximately $120 million to $150 million in injectable revenue. We see that as a key growth driver in next five years. As you know, that we have the great R&D capabilities and our focus has turned more into injectables as well as biosimilars and specialty products so we will expand that. The 15 complex products we expect to launch over 18 to 24 months, which we have launched four already which includes both. So these are complex products only. We do have other product launches as well this year. So, I just want to make sure we're not confusing the street by 15 only, it's 15 plus I call it regular products.
Balaji Prasad -- Barclays -- Analyst
Thank you.
Operator
The next question today comes from Randall Stanicky of RBC Capital Markets. Please go ahead.
Randall Stanicky -- RBC Capital Markets -- Analyst
Great. Thanks, guys. How much new launch revenue have you built into the outlook for 2020? And how does that compare to how you're thinking about 2021? Is it more, is it less on a relative basis? And then the follow-up question just on opioids, how are you guys currently thinking about the opioid exposure? And what are the next data points from an Amneal perspective that we should be focused on? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
Good morning, Randall. On -- we have significant new revenues obviously with Carafate and NuvaRing launched in December. We have not broken it down so -- but let's call it a significant and in 2021 will continue because of the pipeline that we've been investing over years, that all comes to approval cycle over next several years. And we'll keep filing new products as well and we have revamped the R&D to file the products we used to file very high-value products. So very excited about the new product revenues in 2020 and coming years.
On opioid exposure, since we have our GC here, this is Steve Manzano. I'm going to turn it over to him.
Stephen J. Manzano -- Senior Vice President, General Counsel and Corporate Secretary
Thank you, Chirag. Randall on the opioid exposure in terms of data points, I really can't give you any data points that are coming soon. The reason is that we're trying to defend it at the end of the day; it seems that the multi district litigation judge is focusing on promotion activities, as well as distributor activities in terms of the case which Amneal is neither one of those. So we have been purely a generic provider of opioids and have not engaged in promotional activities about the safety and efficacy of the generic opioids that we are -- that to prescribing physicians, patients and for anybody else.
Chirag Patel -- Co-Chief Executive Officer and President
Yes. So there are no activities at this point, Randall.
Randall Stanicky -- RBC Capital Markets -- Analyst
Thanks, guys.
Operator
The next question today comes from Ami Fadia of SVB Leerink. Please go ahead.
Sharon -- SVB Leerink -- Analyst
Hi, this is Sharon [Phonetic] on for Ami. Congratulations on the good quarter and our main question is, you expect about 15 new filings this year, how many of those new launches do you expect this year? And how many of those are that kind of high-value complex generics? And the follow-up question is on IPX203, the timeline seems to have been delayed a few times in the past, what's the main challenge there? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
Yes. Hi, good morning. Just for clarity, we expect to file 20 to 25 new products in year 2020. And we are expected to launch close to 30-plus new launches in year 2020. As far as IPX203, as you know, the always challenge is recruitment and that's why certain timelines have shifted slightly. But we feel very comfortable to have a top line data by first half 2021 and commercialize the product no later than 2023.
Sharon -- SVB Leerink -- Analyst
Could you clarify, among the remaining maybe 11 high-value new launches you identified before, how many can potentially launch?
Chirag Patel -- Co-Chief Executive Officer and President
A good question, but we don't, because certain things are with agency, but we think we'll have few in coming year in 2020. But we are not at this time prepared to give exact number, but we do expect that we will have few in 2020.
Operator
The next question today comes from Gary Nachman of BMO Capital Markets. Please go ahead.
Gary Nachman -- BMO Capital Markets -- Analyst
Hi, good morning. Maybe you can provide a general comment on how challenging the environment has been for new complex launches, like NuvaRing and Carafate versus the way it was over the last couple of years, it seems like you're grabbing some good share. Are you giving up a fair amount of price in order to be able to do that?
And then just a quick follow-up on the generic gross margin, how long will it take to get to the greater than 40% goal? Just lay out the path for that, maybe you could get there in 2021 if you do high 30s like you said in 2020? Thank you very much.
Chirag Patel -- Co-Chief Executive Officer and President
Yes. Good morning, Gary. Nice questions. So, your first question is on the new key product launches on Carafate and NuvaRing. The market share dynamic stays the same except for the complex products, nobody builds out a 100% capacity because it requires all the capital investments, and we expect the competitors to be there. The pricing side, as you know, the three major buying groups have come down hard on generic manufacturers over the last three years, and the profitability what used to be has reduced for even the first two market products.
Your second question on gross margin, the four drivers we have been working on it, since we came back the plant utilization, the efficiency in supply chain, the new product launches and operations excellence, all of them are showing results. As we continue on, as we said high 30s, our run rate would be in 40s by fourth quarter, so we expect to get that as soon as possible, complete focus is on that.
Gary Nachman -- BMO Capital Markets -- Analyst
Okay. Thank you.
Operator
And our last question today comes from Dana Flanders of Guggenheim Securities. Please go ahead.
Dana Flanders -- Guggenheim Securities -- Analyst
Hi, thanks for squeezing me in. Just two quick ones. First, has the supply situation for your generic Epinephrine improved at all, and kind of what's the outlook for that product in 2020? And then my second one actually is on just IPX203, I know you have some data, Phase 2 data expected soon, how do you think about the incremental benefit you need to see over Rytary to get both kind of physicians and payers on board to switch with Rytary generics expected five, six years from now? Thanks.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Dana, good morning. On an EpiPen supply, it's been stable to our expectations from Pfizer. So we're in an OK situation. We could use more but this is what we have forecasted, and we are getting it. So a good job by the hospital plant in the Pfizer on a supply at this point. IPX203 Phase 3, we expect the top line results in first half. And it's a meaningful improvement over IR and over Rytary as well.
We have a pretty good coverage on Rytary, and we expect the coverage to improve as our KOL and initial feedback our CMO, everybody's excited on IPX203 because its duration is good on time, it's six to eight hours compared to three to four hours on Rytary, and the fluctuations are much -- almost half than the IR products. So, very excited about 203, it can expand the market, we will have more proactive commercial strategies than the Rytary when that was launched back a few years ago. Since we have learned a lot, and we're with the community all the time, so very excited about 203. Joe, would you like to add any?
Joseph Todisco -- Senior Vice President, Specialty Commercial
No, I'd say we're putting the framework in place now with the agreements we have on Rytary to lay the ground for the launch of IPX203. So, we're confident at the point of launch, we'll have meaningful managed care coverage on the board.
Chirag Patel -- Co-Chief Executive Officer and President
Thank you, Joe.
Dana Flanders -- Guggenheim Securities -- Analyst
Thank you.
Operator
This concludes our question-and-answer session. I would like to turn the conference back over to Todd Branning for any closing remarks.
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Thank you, operator. I would just close by saying we appreciate you joining our call this morning. And we look forward to our ongoing dialogue with you. And with that, we wish you all a good day. Thank you.
Operator
[Operator Closing Remarks]
Duration: 55 minutes
Call participants:
Todd P. Branning -- Senior Vice President and Chief Financial Officer
Chirag Patel -- Co-Chief Executive Officer and President
Chintu Patel -- Co-Chief Executive Officer
Stephen J. Manzano -- Senior Vice President, General Counsel and Corporate Secretary
Joseph Todisco -- Senior Vice President, Specialty Commercial
Elliot Wilbur -- Raymond James -- Analyst
David Amsellem -- Piper Sandler -- Analyst
Gregg Gilbert -- SunTrust -- Analyst
Chris Schott -- JPMorgan -- Analyst
Balaji Prasad -- Barclays -- Analyst
Randall Stanicky -- RBC Capital Markets -- Analyst
Sharon -- SVB Leerink -- Analyst
Gary Nachman -- BMO Capital Markets -- Analyst
Dana Flanders -- Guggenheim Securities -- Analyst
